Following a daylong meeting on Tuesday, an FDA expert panel voted to recommend a label update for Novo’s blockbuster diabetes drug Victoza stating the med can lower cardiovascular risks for high-risk Type 2 diabetes patients.
Competing with Sanofi blockbuster Lantus is no easy task, but that's exactly what Novo Nordisk's long-acting insulin Tresiba has to do. Thanks to new data, though, the drugmaker can safely say its newcomer poses no increased heart risks—and it...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):